DNA diagnostics market to reach $24.7b by 2034 on precision medicine, genomic advancements

Asia-Pacific emerges as a key growth region.

The global DNA diagnostics market is projected to grow from $13.2b in 2025 to $24.7b by 2034.

According to DelveInsight’s DNA Diagnostics Market Insights report, growth is driven by the rising burden of genetic and infectious diseases, increasing adoption of precision medicine, and advancements in molecular diagnostic technologies.

Market growth is supported by innovations in polymerase chain reaction (PCR), next-generation sequencing (NGS), microarrays, and CRISPR-based diagnostics, which are improving testing accuracy, speed, and accessibility.

The growing focus on early disease detection, cancer genomics, and companion diagnostics is accelerating the adoption of DNA-based testing for identifying genetic mutations, guiding targeted therapies, and improving patient outcomes.

Expanding government investments in genomics research, screening programs, and precision medicine initiatives are further supporting market growth.

Rising consumer awareness of preventive healthcare, increased use of direct-to-consumer genetic testing, advancements in prenatal and newborn screening, and the integration of artificial intelligence and bioinformatics are creating new opportunities for DNA diagnostics companies.

Asia-Pacific is emerging as a key growth region for the DNA diagnostics market, supported by a large patient population, increasing prevalence of chronic and infectious diseases, improving healthcare infrastructure, and growing investments in genomics.

Countries such as China, India, Japan, and South Korea are accelerating adoption through precision medicine programs and government-backed genomic initiatives.

The expanding use of PCR and NGS technologies in infectious disease detection and cancer diagnostics is expected to further strengthen regional growth.

The DNA diagnostics market is set for continued expansion as healthcare systems shift toward personalised medicine, preventive care, and genomic-based solutions.